Immutep LimitedIMMPannounced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial.
Part B evaluates Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc’sMRK Keytruda (pembrolizumab) in 36 patients.
Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standard of care chemotherapy options in this 2nd line setting.
Favorable sustained survival with 36.5% of patients alive at 18 months.
Disease Control Rate (DCR) was 36.1%, and disease control (progression-free) in 25% of patients at six months.
Durable responses of 10+ months in 5.6% (2/36) of patients, with both patients continuing in the trial for over 11 months and 24+ months.
Efti, combined with pembrolizumab, continues to be safe and well-tolerated, with no new safety signals.
Efti’s good safety profile to date compares favorably to the standard of care chemotherapy options.
Price Action: IMMP shares are down 1.77% at $2.22 during the market session on the last check Monday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
